DLD Asset Management »

Acelyrin shares owned by DLD Asset Management

Quarter-by-quarter ownership of Acelyrin (SLRN) shares owned by DLD Asset Management from 13F filings

Historical chart of DLD Asset Management investment in Acelyrin

Tip: Access up to 7 years of quarterly data

All positions including Acelyrin held by DLD Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acelyrin by DLD Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $175k 26k 6.74

More positions owned by DLD Asset Management

Cinemark Hldgs Note 4.500% 8/1 (Principal)
Sarepta Therapeutics DBCV 1.500%11/1 (Principal)
Zscaler Incorporated (ZS)
Ziff Davis Note 1.750%11/0 (Principal)
Starwood Ppty Tr Note 6.750% 7/1 (Principal)
Varex Imaging Corp Note 4.000% 6/0 (Principal)
Patrick Inds Note 1.750%12/0 (Principal)
Livent Corp Note 4.125% 7/1 (Principal)
Transocean Deb 4.625% 9/3 (Principal)
Middleby Corporation (MIDD)
Integer Hldgs Corp Note 2.125% 2/1 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Stride Note 1.125% 9/0 (Principal)
Ncl Corp Note 1.125% 2/1 (Principal)
Infinera Corp Note 3.750% 8/0 (Principal)

View all positions for DLD Asset Management

Top funds holding Acelyrin

Citadel Advisors
BlackRock
Vanguard Group
Millennium Management
OrbiMed Advisors
venBio Partners
T. Rowe Price Investment Management
Blue Owl Capital Holdings
Jpmorgan Chase & Co
Samsara BioCapital
Artal Group
Woodline Partners
Palo Alto Investors
Opaleye Management
Jacobs Levy Equity Management

View all funds holding Acelyrin